Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Freenome, Inc (FRNM : NSDQ)

• Company Description    Freenome is an early cancer detection company developing blood-based screening tests to detect cancer when it is most treatable. The company's Personalized Cancer Detection approach combines multiomics, artificial intelligence and machine learning to develop screening tests tailored to the biology of individual cancers and the needs of specific patient populations. Freenome's first commercial-stage test, SimpleScreen(TM) CRC, is an FDA-approved blood-based screening test for colorectal cancer in adults 45 and older who are at average risk for the disease. Beyond colorectal cancer, Freenome continues to advance a pipeline of non-invasive single- and multi-cancer screening tests across additional cancer indications, in pursuit of its mission to make cancer screening more accessible and increase participation. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $16.32 Daily Weekly Monthly 20 Day Moving Average: 822,783 shares Shares Outstanding: 107.45 (millions) Market Capitalization: $1,753.53 (millions) Beta: 0.44 52 Week High: $17.50 52 Week Low: $9.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.06% 0.01% 12 Week 51.11% 48.23% Year To Date 25.25% 11.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 51 ASTOR PLACE 10TH FLOOR - NEW YORK,NY 10003 USA ph: 212-284-2300 fax: - None http://www.perceptivelife.com/pcsc

• General Corporate Information    Officers Adam Stone - Chief Executive Officer Joseph Edelman - Chairman Sam Cohn - Chief Financial Officer Mark C. McKenna - Director Kenneth Song - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Medical Services Sector: Medical CUSIP: 35661P100 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 107.45 Most Recent Split Date: (:1) Beta: 0.44 Market Capitalization: $1,753.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 173.75 Price / Sales: - EPS Growth vs. Year Ago Period: -114.29% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - - 03/31/26 - -2.70 ROA 09/30/26 - - 06/30/26 - -0.84 03/31/26 - 0.12 Current Ratio 09/30/26 - - 06/30/26 - 0.20 03/31/26 - 0.23 Quick Ratio 09/30/26 - - 06/30/26 - 0.20 03/31/26 - 0.23 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - -0.61 03/31/26 - -0.63 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - -

Powered by Zacks Investment Research ©